Search - tctmd.com

Displaying 601 - 620 of 625

Sort: Relevancy | Date

Presentation

Cost-effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: S. Lee

June 05, 2012

News Daily News

Watchman Works Just as Well Without Warfarin-Protected Transition

June 01, 2012

Presentation

Watchman LAA Closure in A-fib Patients with Contraindication to Oral Anticoagulation

Presenter: Vivek Y. Reddy

May 30, 2012

Presentation

Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) vs. Warfarin in Patients with A-fib

Presenter: Corey S. Miller

May 03, 2012

Presentation

Intracranial Hemorrhage in A-fib Patients During Anticoagulation with Warfarin or Dabigatran

Presenter: Robert G. Hart

April 27, 2012

News Daily News

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

Caitlin E. Cox

April 26, 2012

Presentation

Outcomes of Discontinuing Rivaroxaban vs. Warfarin in Patients with Nonvalvular Atrial Fibrillation (A-fib)

Presenter: M. Patel

April 25, 2012

News Conference News ACC 2012

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

L.A. McKeown

March 26, 2012

News Daily News

El Apixaban Previene el ACV en Pacientes con Fibrilación Auricular con independencia de sus Antecedentes de ACV/AIT

L.A. McKeown

March 12, 2012

News Daily News

Apixaban Prevents Stroke in A-fib Patients Irrespective of Previous Stroke/TIA

L.A. McKeown

March 12, 2012

Presentation

Apixaban vs. Aspirin in Patients with A-fib and Previous Stroke or TIA

Presenter: Hans-Christoph Diener

March 08, 2012

News Daily News

Hope Renewed for Novel Anticoagulant Use in ACS

Caitlin E. Cox

October 05, 2011

News Daily News

Rivaroxaban Continues Emergence of New Class of Anticoagulants for A-Fib

Caitlin E. Cox

September 14, 2011

News Daily News

Prothrombin Works as Antidote to Rivaroxaban, Not Dabigatran

L.A. McKeown

September 13, 2011

News Conference News

Novel Anticoagulants Showing Benefits in A-fib Subgroups

August 29, 2011

News Conference News

Apixaban Bests Warfarin in Stroke Prevention for Atrial Fib

August 28, 2011

News Daily News

ROCKET AF Published: Rivaroxaban Matches Warfarin in Treating A-Fib Patients

Caitlin E. Cox

August 10, 2011

News Daily News

Apixaban Increases Major Bleeding in High-Risk ACS Patients

Jason Kahn

July 25, 2011

News Daily News

ARISTOTLE Makes Its Case: Apixaban Noninferior to Warfarin in A-fib

June 24, 2011

News Daily News

Adding Omega-3 Fatty Acids to Dual Antiplatelet Therapy May Reduce Thrombotic Risk

Leah Lawrence

May 26, 2011

Advertisement

Cost-effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

Watchman Works Just as Well Without Warfarin-Protected Transition

Watchman LAA Closure in A-fib Patients with Contraindication to Oral Anticoagulation

Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) vs. Warfarin in Patients with A-fib

Intracranial Hemorrhage in A-fib Patients During Anticoagulation with Warfarin or Dabigatran

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

Outcomes of Discontinuing Rivaroxaban vs. Warfarin in Patients with Nonvalvular Atrial Fibrillation (A-fib)

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

El Apixaban Previene el ACV en Pacientes con Fibrilación Auricular con independencia de sus Antecedentes de ACV/AIT

Apixaban Prevents Stroke in A-fib Patients Irrespective of Previous Stroke/TIA

Apixaban vs. Aspirin in Patients with A-fib and Previous Stroke or TIA

Hope Renewed for Novel Anticoagulant Use in ACS

Rivaroxaban Continues Emergence of New Class of Anticoagulants for A-Fib

Prothrombin Works as Antidote to Rivaroxaban, Not Dabigatran

Novel Anticoagulants Showing Benefits in A-fib Subgroups

Apixaban Bests Warfarin in Stroke Prevention for Atrial Fib

ROCKET AF Published: Rivaroxaban Matches Warfarin in Treating A-Fib Patients

Apixaban Increases Major Bleeding in High-Risk ACS Patients

ARISTOTLE Makes Its Case: Apixaban Noninferior to Warfarin in A-fib

Adding Omega-3 Fatty Acids to Dual Antiplatelet Therapy May Reduce Thrombotic Risk

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content